ERC1 and non-small cell lung carcinoma: The top fusions partners identified in the NSCLC cohort were KIF5B (chr10 p11.22; 66%), CCDC6 (chr10 q21.2; 18.2%), NCOA4 (chr10 q11.23; 2.9%), TRIM24 (chr7 q34; 2%), ERC1 (chr12 p13.33; 1%), and KIAA1468 (chr18 q21.33; 1%) (Table 3 and Supplementary Fig. 1).